Reuters
Published Apr 11, 2024 09:57
Updated Apr 12, 2024 04:53
BERLIN (Reuters) -Novartis said on Thursday it has launched a tender offer to acquire MorphoSys, a German developer of cancer treatments, for an aggregate 2.7 billion euros ($2.9 billion).
Reuters reported in February that Swiss drugmaker Novartis (LON:0QLR) would buy MorphoSys, which had an equity market value of around 1.6 billion euros before the offer was announced.
The Swiss drugmaker said its cash offer price of 68 euros per MorphoSys share corresponds to a premium of 142% on the volume-weighted average price during the last three months, as of the unaffected closing price on Jan. 25.
MorphoSys shares closed at 67.1 euros on April 10.
Novartis, which said the acceptance period begins on Thursday and will end at midnight on May 13, will take MorphoSys private after the deal, which is contingent on certain conditions, including a minimum acceptance threshold of 65%.
MorphoSys, which is headquartered in Planegg, Germany, develops drugs to fight deadly forms of cancers such as myelofibrosis, which is a rare type of bone marrow cancer, and certain types of knotty lymphomas.
The German firm's supervisory and management boards recommended that shareholders accept the offer, saying it would boost its oncology offering.
Both companies expect the deal to close in the first half of this year.
Switzerland's Novartis has been cutting jobs and costs, and spun off its generic drugs business Sandoz (SIX:SDZ) last year, part of a focus on fewer therapeutic areas and geographic markets.
It has said its overall mergers and acquisitions strategy was focused on deals worth less than $5 billion.
Novartis said Deutsche Bank (ETR:DBKGn) is acting as share tender agent and Bank of New York Mellon (NYSE:BK) will serve as American Depository Shares (ADS) tender agent for the offer.
($1 = 0.9307 euros)
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.